Claims for Patent: 10,800,832

Summary for Patent: 10,800,832

Title:	T cell receptors and immune therapy using the same against prame positive cancers
Abstract:	The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
Inventor(s):	Alten; Leonie (Tuebingen, DE), Maurer; Dominik (Moessingen, DE), Bunk; Sebastian (Tuebingen, DE), Wagner; Claudia (Tuebingen, DE), Ferber; Mathias (Paris, FR)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:	16/403,038
Patent Claims:	1. A method of treating a patient who has a PRAME positive cancer, comprising administering to the patient a population of transformed CD8+ T cells expressing at least one vector encoding a T cell receptor (TCR), wherein the TCR comprises a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 2, a CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 3, a CDR1.beta. chain comprising the amino acid sequences of SEQ ID NO: 7, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 9, wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of SLLQHLIGL (SEQ ID NO: 97) in a complex with HLA-A*02, and wherein the cancer is selected from acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the uterus, ureter cancer, and urinary bladder cancer. 2. The method of claim 1, wherein the population of transformed cells are produced by a method comprising isolating a cell from a subject, transforming the cell with at least one vector encoding the TCR to produce a transformed cell, and expanding the transformed cell to produce the population of transformed cells. 3. The method of claim 2, wherein the subject is the patient. 4. The method of claim 2, wherein the subject is a healthy donor. 5. A method of treating a patient who has a PRAME positive cancer, comprising administering to the patient a population of transformed CD8+ T cells expressing at least one vector encoding a T cell receptor (TCR), wherein the TCR comprises an .alpha. chain comprising the amino acid sequence of SEQ ID NO: 6 and a .beta. chain comprising the amino acid sequence of SEQ ID NO: 12, wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of SLLQHLIGL (SEQ ID NO: 97) in a complex with HLA-A*02, and wherein the cancer is selected from acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the uterus, ureter cancer, and urinary bladder cancer. 6. The method of claim 1, wherein the population of transformed cells are administered in the form of a pharmaceutical composition. 7. The method of claim 6, wherein the pharmaceutical composition comprises a chemotherapeutic agent selected from the group consisting of asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, and vincristine. 8. The method of claim 1, wherein the TCR comprises: a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 2, a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 3, a CDR1.beta. chain comprising the amino acid sequences of SEQ ID NO: 7, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 9. 9. The method of claim 1, wherein the TCR comprises: a CDR1.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 1, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 2, a CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 3, a CDR1.beta. chain consisting of the amino acid sequences of SEQ ID NO: 7, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 9. 10. The method of claim 1, wherein the TCR comprises a CDR1.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 1, a CDR2.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 2, a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 3, a CDR1.beta. chain consisting of the amino acid sequence of SEQ ID NO: 7, a CDR2.beta. chain consisting of the amino acid sequence of SEQ ID NO: 8, and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 9. 11. The method of claim 1, wherein the cancer is melanoma. 12. The method of claim 1, wherein the cancer is bone cancer. 13. The method of claim 10, wherein the cancer is melanoma. 14. The method of claim 10, wherein the cancer is bone cancer.

Details for Patent 10,800,832

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	10,800,832	2039-05-03
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,800,832	2039-05-03